AERO: Adjuvant EveRolimus Outcomes in Laryngotracheal Stenosis

  • STATUS
    Recruiting
  • End date
    Mar 25, 2025
  • participants needed
    20
  • sponsor
    Johns Hopkins University
Send
Updated on 25 October 2022
See if I qualify

Summary

Subglottic stenosis (obstructing scar in the larynx and trachea) occurs in patients spontaneously (idiopathic), with autoimmune disease, and after long-term breathing tube placement and can result in communication disability and high mortality rates due to the obstructed airway. The proposed Adjuvant EveRolimus Outcomes (AERO) trial is proof-of-concept study using the immunosuppressant drug, everolimus, to reduce the number of surgeries for patients with idiopathic Subglottic Stenosis (iSGS). Success with the AERO trial will allow for everolimus to be used in subsequent larger trials of participants with laryngotracheal stenosis and could lead to everolimus being the first FDA approved medical treatment for iSGS.

Details
Condition Idiopathic Subglottic Tracheal Stenosis
Treatment Everolimus Oral Tablet
Clinical Study IdentifierNCT05153668
SponsorJohns Hopkins University
Last Modified on25 October 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Current diagnosis of laryngotracheal stenosis
Patient age 18 - 80 years old
ECOG performance status of 0 - 1
Serum total bilirubin and SGPT (ALT) < 2.0 times the upper limit of normal
Serum creatinine < 2.0 mg/dL
The patient must be able to comprehend and have signed the informed consent
The patient must have documentation of their date of laryngotracheal stenosis diagnosis and prior medical/surgical history
Participants must have also had a prior suspension microlaryngoscopy with endoscopic excision of scar and balloon dilation procedure prior to study entry

Exclusion Criteria

Use of corticosteroids (glucocorticoids) within 7 days of everolimus administration (except physiologic dose equivalent)
Infection requiring treatment with antibiotics, antifungal, or antiviral agents within 7 days of registration
Participation in any clinical trial within 21 days of bone marrow collection involving an investigational drug or device
History of malignancy within five years of registration, except adequately treated basal or squamous cell skin cancer
History of an autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus) requiring active systemic treatment. Hypothyroidism without evidence of Grave's disease or Hashimoto's thyroiditis is permitted
HTLV 1 or 2 positive
NYHA class II-IV heart failure within the past 6 months
History of organ transplant with use of immunosuppression
Current use of immunosuppression
Contraindication or documented intolerance to everolimus
Women of childbearing potential who are not on highly effective contraception or abstinent for at least 30 days. Highly effective contraception includes at least two forms of concurrent contraception (Condoms, oral contraceptives, intrauterine devices, contraceptive implants)
Women who are pregnant or breastfeeding, or wishing to become pregnant are excluded from this study
Current use of cytochrome P450 3A inducers (such as some anticonvulsants, rifampin, isoniazid, St. John's wort)
Current use of cytochrome P450 3A inhibitors (such as azole antifungals, nondihydropyridine calcium channel blockers, some macrolide antibiotics, grapefruit) can result in significant interactions
Baseline proteinuria as defined by urine dipstick analysis
History of angioedema
Baseline/continued use of drugs known to be associated with angioedema including angiotensin converting enzyme inhibitors
Significant pulmonary disease independent of laryngotracheal stenosis as defined by and FEV1/FVC < 10% of the expected value for the patient's age
Evidence of a COVID-19 infection including anosmia, upper respiratory symptoms or positive test result within the 30 days prior of trial participation
Patients who are not fully vaccinated for COVID 19 for at least 4 weeks prior to study entry
Immunosuppressive therapy within previous 21 days or expected need for immunosuppressive therapy for the duration of the study
Known immunodeficiency
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note